In this issue:
Pembrolizumab + platinum-based chemotherapy in squamous NSCLC
Lorlatinib in ALK + NSCLC in first-line or later therapy
Avelumab vs docetaxel in platinumtreated advanced NSCLC
CNS efficacy of osimertinib vs standard EGFR TKIs in EGFR-mutant NSCLC
Resistance mechanisms to osimertinib in EGFR-mutant NSCLC
Disease characteristics of BRAF-mutant NSCLC
Evaluating advanced MET exon 14-altered lung cancers
Luminespib active in NSCLC harbouring EGFR exon ins20
CNS-penetrant TKIs needed for ROS1+ NSCLC
Please login below to download this issue (PDF)